Navidea Biopharmaceuticals Inc. received initial notice of award for a Fast Track Small Business Innovation Research (SBIR) grant up to $1.8 million from the National Cancer Institute (NCI), National Institutes of Health (NIH). The grant will be used to fund preclinical studies examining the safety of intravenous (IV) injection of Tc99m tilmanocept, a Manocept platform product.

Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for invasive tests in up to 61 percent of patients with chest pain and suspected coronary artery disease. The results were presented at the European Society of Cardiology (ESC) Congress 2015.

Significant national and international momentum is building to include a proton therapy unit as part of the planned expansion of SAHMRI, South Australia’s Health and Medical Research Institute. It would be the first facility in the Southern Hemisphere to deliver proton therapy.

Men with relatively unaggressive prostate tumors whose disease is carefully monitored by urologists are unlikely to develop metastatic prostate cancer or die of their cancers, according to a study from the Brady Urological Institute at Johns Hopkins.

Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical Imaging (PMI) with the 2015 European Frost & Sullivan Award for Technology Leadership.

Researchers using functional magnetic resonance imaging (fMRI) have found that even first-episode psychotic patients process information differently from a control group.

Fifty-seven percent of American women believe they should receive a mammogram annually, according to the Truven Health Analytics-NPR Health Poll. However, the U.S. Preventive Services Task Force (USPSTF) issued guidance earlier this year which suggested that women should get a mammogram every two years starting at age 50, provided they do not have a family history or find a lump.